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Introduction
Bacteroides fragilis is an anaerobic Gram-negative bacillus 
and represents a common cause of endogenous infections 
in humans. It is a component of the normal flora in human 
terminal ileum, the colon and the vagina and is frequently 
associated with polymicrobial infections such as intra-
abdominal, diabetic foot and obstetric-gynecologic tract. This 
microorganism is an uncommon cause of endocarditis and 
a few cases in the literature have been described. Its exact 
frequency is difficult to surmise due to the lack of adequate 
methods for their isolation and the identification requiring 
appropriate techniques of collection, transportation and 
cultures of specimens.1 Herein we report a case of Bacteroides 
fragilis endocarditis associated with portal and superior 
mesenteric venous thrombosis in a patient without preexisting 
valvular heart disease and review the cases of endocarditis 
due to this microorganism in the English-language medical 
literature since 1980.
Case presentation
A 64-year-old male was referred to the hospital with a two-
month history of fever, chills, anorexia and general weakness. 
Past medical history was unremarkable except for a dental 
infection treated with amoxicillin fifteen days before the 
fever started and a colonoscopy which showed diverticulosis 
in a routine exam six months prior. During ambulatory 
care he had a normal transthoracic echocardiography and 
abdominal ultrasonography one week before his admission. 
Two sets of aerobic blood cultures were collected at that 
time and remained sterile. Upon hospital admission his 
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physical examination showed body temperature of 39.1oC, 
blood pressure of 120/70 mm Hg, pulse rate of 100 beats/min, 
painless hepatomegaly, normal heart sounds, no sign of 
petechiae or evidence of peripheral emboli and normal 
fundoscopy. Laboratory tests were collected including 
three sets of blood cultures and empirical treatment 
with intravenous aqueous crystalline penicillin 4 MU six 
times daily plus gentamicin 1.5 mg/kg three times daily 
was prompt initiated as a routine antibiotic regimen used 
at our institution for subacute endocarditis. Laboratory 
studies showed hemoglobin of 11 g/dL, white blood cell 
count of 10.300/mm3 with a differential count of 66% 
neutrophils, 11% bands and 20% lymphocytes, platelet count 
398.000/mm3, aspartate and alanine aminotransferase were 
normal, urea nitrogen 26 mg/dL, and creatinine 1,2 mg/dL. 
Studies of coagulation factors, urinalysis and chest 
radiography were normal. Abdominal ultrasonography 
showed thrombosis of the portal vein without collateral blood 
flow or portal hypertension and computed tomography scan 
revealed portal and superior mesenteric vein thrombosis. On 
day two of his admission, anticoagulation was initiated with 
subcutaneous low-molecular-weight heparin (enoxaparin) 
at a dosage of 1 mg/kg twice daily. Colonoscopy confirmed 
diverticulosis with no signs of acute inflammatory process. 
Transesophageal echocardiogram was conducted and 
showed small vegetation (not sized) on the aortic valve 
without regurgitation. Four days after antibiotic therapy 
was initiated, the patient remained febrile and two new 
sets of blood cultures were drawn. On day five of the 
patient admission, two of the three initial sets and the last 
sample of anaerobic blood cultures yielded B. fragilis 
susceptible to metronidazole, amoxicillin/clavulanate, 
clindamycin, imipenem/cilastatin, piperacillin/tazobactam 
and resistant to penicillin. Identification of the B. fragilis 
strain was performed in the automatic ATB Expressions 
system (bioMérieux – France)  using biochemical API 20 A® 
or Vitek ANC card (bioMérieux – France). Minimal inhibitory 
concentrations (MICs) were determined according to the 
reference agar dilution method described by the Clinical and 
Laboratory Standards Institute (CLSI, formerly NCCLS).
Therefore, the antibiotic therapy was switched to 
monotherapy with intravenous metronidazole at a dosage of 
500 mg three times daily according to susceptibility testing. 
Three days later, he became afebrile with improvement of 
overall condition. The patient was treated with intravenous 
metronidazole for four weeks without any adverse effects 
and was discharged home with oral anticoagulation (warfarin 
potassium) for six months, discontinued after abdominal 
ultrasonography revealed complete disappearance of the 
thrombus in the portal vein. His one-year follow-up showed 
no signs of recurrent infection.
Discussion
Bacteroides fragilis is an anaerobic Gram-negative rod and 
constitutes 1% to 2% of the normal colonic bacterial microflora 
in humans.2 However, these organisms can also be responsible 
for infections of endogenous origin including dental abscess, 
peritonitis, cholecystitis, appendicitis, aortoduodenal fistula, 
obstetric-gynecologic, diabetic foot and skin structure 
infections.3 Because of their fastidious nature, they are difficult 
to isolate from infectious sites and are often overlooked.4
Endocarditis due to anaerobic bacteria is an uncommon event 
and endocarditis due to Bacteroides fragilis is rarely reported. 
We performed a review of literature in MEDLINE 
(source PubMed) from 1980 to 2009 and found eight cases 
of endocarditis due to Bacteroides fragilis. We also reviewed 
the list of references of review articles and excluded the 
repeated cases related to previous studies. The characteristics 
of reported cases (including the present report) are shown 
in Table 1.5-11 Elderly patients (mean age, 59 years; range, 
14-78 years) were mostly affected and the presence of prior 
heart or valvular disease in this population are common 
findings (78%). In 1970, Felner and Dowell3 described 11 cases 
of endocarditis due to B. fragilis and the clinical features are 
showed in Table 2.
The development of infective endocarditis depends 
on the ability of bacteria to adhere to the vascular 
endothelium and the capacity to invade valvular leaflets.12 
In this context, two characteristics of Bacteroides fragilis 
are important: invasiveness and production of toxins. 
Invasiveness can lead to damage in the local tissue while 
toxins can be transported to other sites causing much more 
damage than the original lesion.1 Its pathogenicity has 
been attributed to several virulence factors including the 
lipopolysaccharide (LPS), the polysaccharide capsule and 
a variety of enzymes (protease, heparinase, collagenase, 
haemolysin) which protect it of the host immune system. 
The LPS is responsible for abscess formation and histolytic 
enzymes can mediate tissue destruction, common events 
found in infections caused by these bacteria.13
Valvular destruction, aortic-ring abscess, congestive heart 
failure, cardiogenic shock dysrhythmias and thromboembolic 
events1,3 are the most important complications in endocarditis 
due to B. fragilis. Among the 9 available reported cases (Table 1), 
3 patients (33%) had congestive heart failure or cardiogenic 
shock, 3 (33%) had valvular destruction/abscess and 3 (33%) 
had thromboembolic events.
Thromboembolism is common in patients with 
endocarditis due to aerobic bacteria occurring in 20-25% of 
cases14 and decreased when adequate therapy was started 
early.15 In this review, thromboembolic events occurred in 
33% (3/9), not significantly more common than described 
in endocarditis caused by others agents.
Here, we described a case of endocarditis due to B. 
fragilis with an asymptomatic local thrombosis (portal and 
mesenteric vein), frequently associated with more than one 
risk factor not found in this patient, including neoplasia, 
cirrhosis, gastrointestinal infection, myeloproliferative 
disorders, thrombophilia, pregnancy, or liver transplantation. 
There is a possible pathogenic role of prothrombotic 
phenomena during an invasive B. fragil is  infection 
probably associated with heparinase production by 
these microorganisms.12 This enzyme can accelerate the 
intravascular clotting and may contribute with thrombus 
formation. In mice, Bacteroides can trigger coagulation 
probably secondary to a cell-wal component.16 Surface 
102 BRAZ J INFECT DIS. 2012;16(1):100-104
A
u
th
or
 
 
n
 
 
S
ex
/a
ge
  
 
Pr
io
r 
h
ea
rt
 o
r 
va
lv
u
la
r 
d
is
ea
se
 
V
al
ve
 
af
fe
ct
ed
 
Pr
ed
is
p
os
in
g 
 
co
n
d
it
io
n
s 
Pr
ob
ab
le
 
so
u
rc
e 
of
 
in
fe
ct
io
n
D
u
ra
ti
on
 o
f 
sy
m
p
to
m
s 
D
ia
gn
os
is
 
 
C
om
p
li
ca
ti
on
s 
 
T
h
er
ap
y 
 
O
u
tc
om
e 
 
T
ab
aq
ch
al
i e
t 
al
.5
1
M
/1
4
N
R
A
or
ti
c 
 
p
ro
st
h
es
is
N
on
e
N
R
N
R
B
lo
od
  
cu
lt
u
re
C
on
ge
st
iv
e 
 
h
ea
rt
 f
ai
lu
re
C
ep
 +
 M
et
Su
rg
er
y
C
u
re
d
Es
te
ba
n
 e
t 
al
.6
1
M
/5
4
Is
ch
em
ic
 h
ea
rt
  
d
is
ea
se
N
on
e
C
ol
it
is
G
as
tr
oi
n
te
st
in
al
  
tr
ac
t
2 
w
ee
ks
B
lo
od
  
cu
lt
u
re
M
yo
ca
rd
ia
l a
bs
ce
ss
, 
se
p
ti
c 
sh
oc
k,
  
ce
re
br
al
 e
m
bo
li
sm
A
m
p
 +
 G
t
C
h
l/
C
fx
D
ie
d
Ja
ck
so
n
 a
n
d
 D
op
p
7
1
M
/7
8
A
or
ti
c 
va
lv
e 
 
sc
le
ro
si
s
A
or
ti
c 
 
va
lv
e
D
iv
er
ti
cu
lu
m
 
of
 t
h
e 
co
lo
n
 
an
d
 e
so
p
h
ag
u
s 
(Z
en
ke
r’
s)
G
as
tr
oi
n
te
st
in
al
  
tr
ac
t
6 
w
ee
ks
B
lo
od
  
cu
lt
u
re
N
on
e
Pi
p
Im
p
 +
 M
et
A
m
x/
C
lv
C
u
re
d
Lo
rt
h
ol
ar
y 
et
 a
l.8
1
F/
78
A
or
ti
c 
 
st
en
os
is
A
or
ti
c 
 
p
ro
st
h
es
is
O
va
ri
an
 
ca
rc
in
om
a,
 
sm
al
l b
ow
el
 
oc
cl
u
si
on
G
as
tr
oi
n
te
st
in
al
  
tr
ac
t
1-
2 
w
ee
ks
B
lo
od
 a
n
d
 
p
ro
st
h
et
ic
  
va
lv
e 
 
cu
lt
u
re
C
ar
d
io
ge
n
ic
  
sh
oc
k
C
tx
 +
 S
b 
 
+
 O
rn
 +
 A
m
c
D
ie
d
B
is
h
ra
ra
t 
et
 a
l.9
2
F/
74
A
or
ti
c 
 
st
en
os
is
A
or
ti
c 
 
p
ro
st
h
es
is
C
ol
on
ic
  
n
eo
p
la
si
a
G
as
tr
oi
n
te
st
in
al
  
tr
ac
t
2 
w
ee
ks
B
lo
od
  
cu
lt
u
re
N
on
e
M
et
C
u
re
d
F/
50
R
h
eu
m
at
ic
 h
ea
rt
 
d
is
ea
se
 (a
or
ti
c 
 
st
en
os
is
 +
 m
it
ra
l 
re
gu
rg
it
at
io
n
)
A
or
ti
c 
 
va
lv
e
En
d
om
et
ri
al
  
n
eo
p
la
si
a
G
en
it
al
  
tr
ac
t
1-
2 
w
ee
ks
B
lo
od
  
cu
lt
u
re
M
yo
ca
rd
ia
l a
bs
ce
ss
, 
co
n
ge
st
iv
e 
h
ea
rt
  
fa
il
u
re
M
et
D
ie
d
Le
 G
of
f 
et
 a
l.1
0
1
M
/7
3
Is
ch
em
ic
 h
ea
rt
  
d
is
ea
se
A
or
ti
c 
 
va
lv
e
D
iv
er
ti
cu
lo
si
s,
 
d
ia
be
te
s
G
as
tr
oi
n
te
st
in
al
  
tr
ac
t
3 
w
ee
ks
B
lo
od
  
cu
lt
u
re
T
h
ro
m
bo
si
s 
of
 t
h
e 
p
or
ta
l v
ei
n
Pi
p
 +
 M
et
C
u
re
d
B
ac
h
io
n
 e
t 
al
.1
1
1
M
/4
6
B
ic
u
sp
id
 a
or
ti
c 
 
va
lv
e
A
or
ti
c/
m
it
ra
l  
va
lv
e
D
en
ta
l a
bs
ce
ss
G
as
tr
oi
n
te
st
in
al
  
tr
ac
t
N
R
B
lo
od
  
cu
lt
u
re
Pe
ri
va
lv
ar
  
ab
sc
es
s
Im
p
 +
 G
t 
su
rg
er
y
C
u
re
d
PR
1
M
/6
4
N
on
e
A
or
ti
c 
 
va
lv
e
D
iv
er
ti
cu
lo
si
s
G
as
tr
oi
n
te
st
in
al
  
tr
ac
t
8 
w
ee
ks
B
lo
od
  
cu
lt
u
re
T
h
ro
m
bo
si
s 
of
 t
h
e 
p
or
ta
l a
n
d
 s
u
p
er
io
r 
m
es
en
te
ri
c 
ve
in
M
et
C
u
re
d
A
m
p
, a
m
p
ic
il
li
m
; A
m
k,
 a
m
ik
ac
in
; A
m
x/
C
lv
, a
m
ox
ic
il
li
n
/c
la
vu
la
n
at
e;
 C
ep
, c
ef
u
ro
xi
m
e;
 C
tx
, c
ef
ot
ax
im
e;
 C
h
l, 
ch
lo
ra
m
p
h
en
ic
ol
; C
fx
, c
ef
ox
it
in
; G
t,
 g
en
ta
m
ic
in
; I
m
p
, i
m
ip
en
em
; M
et
, m
et
ro
n
id
az
ol
e;
 
N
A
, n
ot
 a
p
p
li
ca
bl
e;
 O
rn
, o
rn
id
az
ol
e;
 O
xc
, o
xa
ci
ll
in
; P
en
, p
en
ic
il
li
n
; P
R
, p
re
se
n
t 
re
p
or
t;
 S
b,
 s
u
lb
ac
ta
m
; N
R
, n
ot
 k
n
ow
n
 o
r 
n
ot
 r
ep
or
te
d
.
T
ab
le
 1
 -
 C
h
ar
ac
te
ri
st
ic
s 
of
 e
n
d
oc
ar
d
it
is
 d
u
e 
to
 B
ac
te
ro
id
es
 f
ra
gi
li
s 
si
n
ce
 1
98
0
 BRAZ J INFECT DIS. 2012;16(1):100-104 103
components enhance fibrin clotting with macrophages 
activation and start the clotting cascade.17,18 The other 
factors include the release of procoagulant factors (E-selectin 
and P-selectin) by endothelial cells collaborating with 
the thrombosis, the genetic thrombophilia (protein S and 
protein C deficiency, prothrombin gene mutation, factor 
V Leiden mutation), a transient development of anti-
cardiolipin antibodies19 and other prothrombotic disorders 
(antiphospholipid syndrome, neoplasms).20 In summary, the 
pathogenic role of Bacteroides in thromboembolic events is 
unclear and more thorough studies are needed to clarify this 
controversial issue.
The signs and symptoms, physical examination and 
laboratory tests found in endocarditis due to B. fragilis are 
similar to those seen in endocarditis due to other bacteria. The 
real role of anticoagulation therapy in documented superior or 
inferior mesenteric vein thrombosis is controversial but may 
be considered in patients with normal clotting function.21 
Early anticoagulation could reverse or prevent progression of 
thrombosis thus minimizing the risk of bowel ischemia and 
infarction and improved outcome with a high recanalization 
rate, lower portal hypertension and mortality.22 The etiology of 
underlying hypercoagulable disorder should be studied19 but in 
most cases, the infection is responsible for this acute disorder.
The treatment of infective endocarditis should be done with 
bactericidal antimicrobials agents. Appropriate antimicrobial 
therapy is associated with lower mortality and empiric anti-
biotic therapy should be started immediately after collection 
of cultures. Nitroimidazoles (metronidazole), carbapenems 
(imipenem, meropenem, ertapenem and doripenem), 
combinations of β-lactams with a β-lactamase inhibitor 
(clavulanate, sulbactam and tazobactam) and some quinolones 
(moxifloxacin) have a good activity against B. fragilis22 and can be 
used in the treatment of endocarditis caused by these bacteria.
Despite the small number of cases reported and the limited 
experiences in treating B. fragilis endocarditis, we suggested 
the administration of intravenous metronidazole for 
4-6 weeks, based on other reported cases. Other antimicrobial 
agents with bactericidal activity against B. fragilis, such 
imipenem, amoxicillin-clavulanate and piperacillin-
tazobactam, could be adequate alternatives with relatively 
low toxicity in the treatment of endocarditis due these 
bacteria.
In the last three decades, the mortality and thromboembolic 
events decreased, probably due to early diagnosis and 
introduction of metronidazole, a potent antimicrobial agent 
with good bactericidal activity against Bacteroides.23
Conclusion 
In summary, endocarditis due to Bacteroides fragilis could be 
considered in elderly individuals with preexisting valvular or 
heart disease and unexplained fever for more than two weeks, 
anemia, malaise and a previous history of gastrointestinal tract 
manipulation or disorder. We emphasize that Bacteroides fragilis 
is a rare agent of endocarditis and these patients should be 
carefully evaluated for the complications associated with this 
anaerobic infection.
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